Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Primary Sclerosing Cholangitis (PSC) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Primary Sclerosing Cholangitis (PSC) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Primary Sclerosing Cholangitis (PSC) Overall Market Size
2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size: 2022 VS 2029
2.2 Global Primary Sclerosing Cholangitis (PSC) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Primary Sclerosing Cholangitis (PSC) Players in Global Market
3.2 Top Global Primary Sclerosing Cholangitis (PSC) Companies Ranked by Revenue
3.3 Global Primary Sclerosing Cholangitis (PSC) Revenue by Companies
3.4 Top 3 and Top 5 Primary Sclerosing Cholangitis (PSC) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Primary Sclerosing Cholangitis (PSC) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Primary Sclerosing Cholangitis (PSC) Players in Global Market
3.6.1 List of Global Tier 1 Primary Sclerosing Cholangitis (PSC) Companies
3.6.2 List of Global Tier 2 and Tier 3 Primary Sclerosing Cholangitis (PSC) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Primary Sclerosing Cholangitis (PSC) Market Size Markets, 2022 & 2029
4.1.2 Medical Treatement
4.1.3 Liver Transplantation
4.1.4 Others
4.2 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue & Forecasts
4.2.1 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2023
4.2.2 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2024-2029
4.2.3 By Type - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Primary Sclerosing Cholangitis (PSC) Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue & Forecasts
5.2.1 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2023
5.2.2 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2024-2029
5.2.3 By Application - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Primary Sclerosing Cholangitis (PSC) Market Size, 2022 & 2029
6.2 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue & Forecasts
6.2.1 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2023
6.2.2 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue, 2024-2029
6.2.3 By Region - Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.3.2 US Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.3.3 Canada Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.3.4 Mexico Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.4.2 Germany Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.3 France Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.4 U.K. Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.5 Italy Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.6 Russia Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.7 Nordic Countries Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.4.8 Benelux Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.5.2 China Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.3 Japan Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.4 South Korea Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.5 Southeast Asia Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.5.6 India Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.6.2 Brazil Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.6.3 Argentina Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Primary Sclerosing Cholangitis (PSC) Revenue, 2018-2029
6.7.2 Turkey Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7.3 Israel Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7.4 Saudi Arabia Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
6.7.5 UAE Primary Sclerosing Cholangitis (PSC) Market Size, 2018-2029
7 Primary Sclerosing Cholangitis (PSC) Companies Profiles
7.1 Acorda Therapeutics
7.1.1 Acorda Therapeutics Company Summary
7.1.2 Acorda Therapeutics Business Overview
7.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.1.4 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.1.5 Acorda Therapeutics Key News & Latest Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Summary
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.2.4 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.2.5 Gilead Sciences Key News & Latest Developments
7.3 NGM Biopharmaceuticals
7.3.1 NGM Biopharmaceuticals Company Summary
7.3.2 NGM Biopharmaceuticals Business Overview
7.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.3.4 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.3.5 NGM Biopharmaceuticals Key News & Latest Developments
7.4 Intercept Pharmaceuticals
7.4.1 Intercept Pharmaceuticals Company Summary
7.4.2 Intercept Pharmaceuticals Business Overview
7.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.4.4 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.4.5 Intercept Pharmaceuticals Key News & Latest Developments
7.5 Dr. Falk Pharma
7.5.1 Dr. Falk Pharma Company Summary
7.5.2 Dr. Falk Pharma Business Overview
7.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.5.4 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.5.5 Dr. Falk Pharma Key News & Latest Developments
7.6 Allergan
7.6.1 Allergan Company Summary
7.6.2 Allergan Business Overview
7.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.6.4 Allergan Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.6.5 Allergan Key News & Latest Developments
7.7 Shire
7.7.1 Shire Company Summary
7.7.2 Shire Business Overview
7.7.3 Shire Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.7.4 Shire Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.7.5 Shire Key News & Latest Developments
7.8 Durect Corporation
7.8.1 Durect Corporation Company Summary
7.8.2 Durect Corporation Business Overview
7.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.8.4 Durect Corporation Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.8.5 Durect Corporation Key News & Latest Developments
7.9 Conatus Pharmaceuticals
7.9.1 Conatus Pharmaceuticals Company Summary
7.9.2 Conatus Pharmaceuticals Business Overview
7.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.9.4 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.9.5 Conatus Pharmaceuticals Key News & Latest Developments
7.10 Sirnaomics
7.10.1 Sirnaomics Company Summary
7.10.2 Sirnaomics Business Overview
7.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.10.4 Sirnaomics Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.10.5 Sirnaomics Key News & Latest Developments
7.11 Shenzhen HighTide Biopharmaceutical
7.11.1 Shenzhen HighTide Biopharmaceutical Company Summary
7.11.2 Shenzhen HighTide Biopharmaceutical Business Overview
7.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.11.4 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.11.5 Shenzhen HighTide Biopharmaceutical Key News & Latest Developments
7.12 Glenmark
7.12.1 Glenmark Company Summary
7.12.2 Glenmark Business Overview
7.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.12.4 Glenmark Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.12.5 Glenmark Key News & Latest Developments
7.13 Impax Laboratories
7.13.1 Impax Laboratories Company Summary
7.13.2 Impax Laboratories Business Overview
7.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.13.4 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.13.5 Impax Laboratories Key News & Latest Developments
7.14 Mylan
7.14.1 Mylan Company Summary
7.14.2 Mylan Business Overview
7.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.14.4 Mylan Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.14.5 Mylan Key News & Latest Developments
7.15 Teva Pharmaceuticals
7.15.1 Teva Pharmaceuticals Company Summary
7.15.2 Teva Pharmaceuticals Business Overview
7.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.15.4 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.15.5 Teva Pharmaceuticals Key News & Latest Developments
7.16 Daewoong Pharmaceutical
7.16.1 Daewoong Pharmaceutical Company Summary
7.16.2 Daewoong Pharmaceutical Business Overview
7.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.16.4 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.16.5 Daewoong Pharmaceutical Key News & Latest Developments
7.17 Mitsubishi Tanabe Pharma
7.17.1 Mitsubishi Tanabe Pharma Company Summary
7.17.2 Mitsubishi Tanabe Pharma Business Overview
7.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.17.4 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.17.5 Mitsubishi Tanabe Pharma Key News & Latest Developments
7.18 Lannett
7.18.1 Lannett Company Summary
7.18.2 Lannett Business Overview
7.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Major Product Offerings
7.18.4 Lannett Primary Sclerosing Cholangitis (PSC) Revenue in Global Market (2018-2023)
7.18.5 Lannett Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer